These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 30997706)

  • 1. Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma.
    Kuwabara S; Tsuchikawa T; Nakamura T; Hatanaka Y; Hatanaka KC; Sasaki K; Ono M; Umemoto K; Suzuki T; Sato O; Hane Y; Nakanishi Y; Asano T; Ebihara Y; Kurashima Y; Noji T; Murakami S; Okamura K; Shichinohe T; Hirano S
    Cancer Sci; 2019 Jun; 110(6):1853-1862. PubMed ID: 30997706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.
    Homma Y; Taniguchi K; Murakami T; Nakagawa K; Nakazawa M; Matsuyama R; Mori R; Takeda K; Ueda M; Ichikawa Y; Tanaka K; Endo I
    Ann Surg Oncol; 2014 Feb; 21(2):670-6. PubMed ID: 24310792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunological impact of preoperative chemoradiotherapy on the tumor microenvironment of pancreatic cancer.
    Okubo S; Suzuki T; Hioki M; Shimizu Y; Toyama H; Morinaga S; Gotohda N; Uesaka K; Ishii G; Takahashi S; Kojima M
    Cancer Sci; 2021 Jul; 112(7):2895-2904. PubMed ID: 33931909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MZB1 in borderline resectable pancreatic cancer resected after neoadjuvant chemoradiotherapy.
    Miyake K; Mori R; Homma Y; Matsuyama R; Okayama A; Murakami T; Hirano H; Endo I
    J Surg Res; 2017 Dec; 220():391-401. PubMed ID: 29180208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer.
    Imaizumi K; Suzuki T; Kojima M; Shimomura M; Sakuyama N; Tsukada Y; Sasaki T; Nishizawa Y; Taketomi A; Ito M; Nakatsura T
    Cancer Sci; 2020 Jan; 111(1):23-35. PubMed ID: 31660687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.
    Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS
    Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
    Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
    Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma.
    Wattenberg MM; Colby S; Garrido-Laguna I; Xue Y; Chang R; Delman D; Lee J; Affolter K; Mulvihill SJ; Beg MS; Wang-Gillam A; Wade JL; Guthrie KA; Chiorean EG; Ahmad SA; Lowy AM; Philip PA; Sohal DPS; Beatty GL
    Gastroenterology; 2024 Jun; 166(6):1114-1129. PubMed ID: 38244727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells.
    Mota Reyes C; Teller S; Muckenhuber A; Konukiewitz B; Safak O; Weichert W; Friess H; Ceyhan GO; Demir IE
    Clin Cancer Res; 2020 Jan; 26(1):220-231. PubMed ID: 31585935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer undergoing upfront surgery.
    van Eijck CWF; Real FX; Malats N; Vadgama D; van den Bosch TPP; Doukas M; van Eijck CHJ; Mustafa DAM;
    Cell Rep Med; 2024 May; 5(5):101557. PubMed ID: 38733987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel aspects of preoperative chemoradiation therapy improving anti-tumor immunity in pancreatic cancer.
    Tsuchikawa T; Hirano S; Tanaka E; Matsumoto J; Kato K; Nakamura T; Ebihara Y; Shichinohe T
    Cancer Sci; 2013 May; 104(5):531-5. PubMed ID: 23363422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncologic impact of preoperative prognostic nutritional index change in resected pancreatic cancer following neoadjuvant chemotherapy.
    Kim KH; Hwang HK; Kang IC; Lee WJ; Kang CM
    Pancreatology; 2020 Mar; 20(2):247-253. PubMed ID: 31889624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer.
    Zwart ES; van Ee T; Doppenberg D; Farina A; Wilmink JW; Versteijne E; Busch OR; Besselink MG; Meijer LL; van Kooyk Y; Mebius RE; Kazemier G
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):14731-14743. PubMed ID: 37587309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Importance of a Conjoint Analysis of Tumor-Associated Macrophages and Immune Checkpoints in Pancreatic Cancer.
    Xu JY; Wang WS; Zhou J; Liu CY; Shi JL; Lu PH; Ding JL
    Pancreas; 2019 Aug; 48(7):904-912. PubMed ID: 31268976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Immune Microenvironment on the Prognosis of Pancreatic Ductal Adenocarcinoma Based on Multi-Omics Analysis.
    Yang B; Zhou M; Wu Y; Ma Y; Tan Q; Yuan W; Ma J
    Front Immunol; 2021; 12():769047. PubMed ID: 34777388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of gender-associated M2-like tumor-associated macrophages in the tumor microenvironment of patients with pancreatic cancer after neoadjuvant chemoradiotherapy.
    Matsuki H; Hiroshima Y; Miyake K; Murakami T; Homma Y; Matsuyama R; Morioka D; Kurotaki D; Tamura T; Endo I
    J Hepatobiliary Pancreat Sci; 2021 Feb; 28(2):174-182. PubMed ID: 33316125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer.
    Sadozai H; Acharjee A; Eppenberger-Castori S; Gloor B; Gruber T; Schenk M; Karamitopoulou E
    Front Immunol; 2021; 12():643529. PubMed ID: 33679807
    [No Abstract]   [Full Text] [Related]  

  • 20. Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study.
    van Eijck CWF; Vadgama D; van Eijck CHJ; Wilmink JW;
    J Natl Cancer Inst; 2024 Aug; 116(8):1374-1383. PubMed ID: 38530777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.